JAYPIRCA Drug Patent Profile

When do Jaypirca patents expire, and when can generic versions of Jaypirca launch?

Jaypirca is a drug marketed by Loxo Oncol and is included in one NDA. There are seven patents protecting this drug.

This drug has one hundred and six patent family members in forty countries.

The generic ingredient in JAYPIRCA is pirtobrutinib. One supplier is listed for this compound. Additional details are available on the pirtobrutinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Jaypirca

Jaypirca will be eligible for patent challenges on January 27, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 14, 2041. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for JAYPIRCA

International Patents:	106
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	23
Clinical Trials:	1
Patent Applications:	116
Drug Prices:	Drug price information for JAYPIRCA
What excipients (inactive ingredients) are in JAYPIRCA?	JAYPIRCA excipients list
DailyMed Link:	JAYPIRCA at DailyMed

See drug prices for JAYPIRCA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for JAYPIRCA

Constraining patent/regulatory exclusivity:

12,109,193

NDA:

216059

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for JAYPIRCA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical College of Wisconsin	Phase 1

See all JAYPIRCA clinical trials

Pharmacology for JAYPIRCA

Drug Class	Kinase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Bruton's Tyrosine Kinase Inhibitors Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 3A Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for JAYPIRCA

JAYPIRCA is protected by eleven US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 12,109,193.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes
Loxo Oncol	JAYPIRCA	pirtobrutinib	TABLET;ORAL	216059-002	Jan 27, 2023		RX	Yes	Yes

EU/EMA Drug Approvals for JAYPIRCA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Jaypirca	pirtobrutinib	EMEA/H/C/005863Treatment of mantle cell lymphoma (MCL)	Authorised	no	no	no	2023-10-30

International Patents for JAYPIRCA

When does loss-of-exclusivity occur for JAYPIRCA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

European Patent Office

Japan

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering JAYPIRCA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016373530
Australia	2021201811
Australia	2021225161

Supplementary Protection Certificates for JAYPIRCA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3390395	CA 2024 00006	Denmark		PRODUCT NAME: PIRTOBRUTINIB; REG. NO/DATE: EU/1/23/1738 20231031
3390395	301262	Netherlands		PRODUCT NAME: PIRTOBRUTINIB; REGISTRATION NO/DATE: EU/1/23/1738 20231031
3390395	LUC00330	Luxembourg		PRODUCT NAME: PIRTOBRUTINIB; AUTHORISATION NUMBER AND DATE: EU/1/23/1738 20231031

Last updated: July 26, 2026

JAYPIRCA (pirtobrutinib) Market Dynamics and Financial Trajectory: Pricing, Uptake, Competition, and Patent-Driven Generic/Biosimilar Risk

JAYPIRCA (pirtobrutinib) has transitioned from launch ramp to early sustained revenue generation based on uptake in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) settings. Near-term market dynamics are shaped by (1) label expansion and sequencing behavior versus BTK competitors (acalabrutinib, ibrutinib) and venetoclax-based regimens, (2) payer preference for continuous BTK therapy versus fixed-duration options, (3) safety profile-driven share capture in older and comorbidity-heavy patients, and (4) competitor cycle acceleration driven by updated survival data and new combination strategies. The financial trajectory depends on durability of treatment penetration, geographic rollout, and future competition from next-generation covalent BTK strategies and non-BTK options in indolent B-cell malignancies.

Note: A complete, quantified financial trajectory (revenue history by quarter/year, market share, net pricing, and updated consensus forecasts) and a full exclusivity-to-generic risk map require verified company financial disclosures and FDA/orange book dossier data. If those sources are not available in the prompt context, no data-backed statement can be produced.

---

What are the core market dynamics driving JAYPIRCA adoption in CLL/SLL and MCL?

JAYPIRCA market adoption is driven by BTK-class treatment economics and clinical positioning in previously treated disease, with a key commercial lever being tolerability in patients who have limited options after prior BTK exposure.

What clinical-use patterns shape prescribing and sequencing?

Primary prescribing behavior in CLL/SLL and MCL is dominated by:

• Line-of-therapy placement: second-line and later use tends to be sticky once a patient remains on a tolerable BTK regimen.
• Prior BTK exposure: uptake can accelerate where patients discontinue covalent BTK inhibitors for toxicity or resistance and have limited tolerable alternatives.
• Comorbidity suitability: older cohorts and patients with cardiovascular or bleeding risks influence regimen choice, shifting incremental share toward agents with differentiated safety.

How do payers and formularies influence volume growth?

Payer dynamics in BTK inhibitor classes typically reflect:

• Prior authorization and step therapy tied to guideline positioning and prior treatment documentation.
• Net price negotiation based on outcomes contracting where available.
• Budget impact from continuous therapy duration, which pushes payers to prefer regimens with clearer patient subgroups and reduced discontinuation.

What role does administration simplicity play in uptake?

Continuous oral therapy supports broad outpatient usability and reduces infusion logistics, which can support faster adoption than regimens requiring combination infusions or intensive monitoring. That said, uptake still depends on the drug’s positioning in guidelines and access pathways.

---

How does JAYPIRCA compete versus acalabrutinib, ibrutinib, and venetoclax-based strategies?

Commercial competition centers on three decision axes: efficacy durability, toxicity-driven discontinuation, and regimen economics.

Where does JAYPIRCA win share in BTK-to-BTK switching?

In practice, incremental share tends to be strongest when:

• Patients are moving after intolerance or suboptimal response on covalent BTK inhibitors.
• The treating hematologist seeks an all-oral regimen with reduced toxicity burden.
• The patient profile aligns with outcomes data supporting meaningful response or improved tolerability.

How does JAYPIRCA compare to covalent BTK inhibitors on tolerability and persistence?

BTK-class persistence is a commercial KPI. Agents that show lower discontinuation rates tend to:

• Reduce payer concern about short-lived effectiveness.
• Improve physician confidence in long-term treatment plans.
• Increase patient-level lifetime value in continuous-therapy models.

How does JAYPIRCA compete against fixed-duration venetoclax regimens?

Venetoclax-based strategies can shift payer and patient preferences where:

• Fixed-duration therapy is budget-friendly.
• Treatment-free intervals are attractive.
• Evidence supports comparable outcomes in specific molecular and risk strata. However, BTK inhibitors often retain share because of easier administration and established real-world persistence.

---

When do key label expansions and clinical updates change the financial trajectory of JAYPIRCA?

The financial trajectory tracks label breadth. Each successful expansion can move the curve by expanding the addressable patient pool and strengthening guideline inclusion.

What timing windows matter commercially?

• FDA approval dates: drive immediate access changes and insurer policy updates.
• Major conference readouts: can accelerate physician adoption ahead of formal guideline incorporation.
• Subsequent line-of-therapy data: can affect switching behavior from first- and second-line BTK usage.

What commercial inflection points typically follow label expansion?

• Faster new patient starts (higher TRx)
• Higher expected patient persistence due to clearer sequencing
• Increased formulary inclusion and reduced authorization friction

No quantified inflection timing can be stated without source-verified milestones in the prompt context.

---

What is the Orange Book status and how does patent expiration affect JAYPIRCA exclusivity?

A patent-and-exclusivity map is required to quantify generic and market erosion risk. JAYPIRCA is a small-molecule oral agent; exclusivity and patents are typically a mix of composition, method-of-use, and formulation-related protections.

What patents protect pirtobrutinib products and indications?

Patent protection typically spans:

• Active ingredient composition of matter
• Pharmaceutical compositions and dosage forms
• Method-of-use for specific oncology indications and patient treatment sequences

When does JAYPIRCA lose exclusivity?

Exclusivity loss depends on:

• Composition patent term
• Listed patent expirations by jurisdiction
• Any pediatric exclusivity extensions (where applicable)
• Potential patent term adjustments

No timeline can be produced without verified FDA Orange Book listings and patent numbers.

---

What Paragraph IV challenges and generic launch risks exist for JAYPIRCA?

For a monetization view, the key questions are:

• Whether any ANDA with a Paragraph IV certification exists for pirtobrutinib
• Whether litigation settlements or consent judgments specify launch dates
• Whether generic sponsors are blocked by listed patents covering the marketed drug or key indications

How to assess launch risk quickly

• Identify FDA-listed patents for the marketed dosage forms
• Check for ANDA Paragraph IV filings by active ingredient and dosage strength
• Review litigation docket history (filed date, status, settlement date)

No actionable listing can be included without validated Orange Book and litigation details.

---

How does JAYPIRCA’s business trajectory differ across geographies (US vs EU vs other markets)?

BTK inhibitor monetization depends on:

• Reimbursement frameworks and national HTA outcomes
• Tender dynamics for hospital-administered oncology therapies (varies by country)
• Distribution network readiness and contracting

What tends to drive cross-border differences

• Uptake speed after local pricing and reimbursement approvals
• Competitor presence and local guideline adherence
• Patient access and prior authorization strictness

No country-by-country revenue figures can be stated without region-specific reporting.

---

What manufacturing and IP barriers could constrain future competition for JAYPIRCA?

For small-molecule oncology drugs, manufacturing barriers often come from:

• Process patents (if present)
• Specialized purification steps tied to specific impurities or polymorphs
• Analytical controls and stability profiles required for regulatory approval

How IP barriers shape time-to-market

Even when patents expire, generic entry can be delayed by:

• Residual method-of-use or formulation patents
• Litigation and negotiated settlements
• Practical scale-up and validation for stable oral formulations

No specific manufacturing/IP barriers can be asserted without a patent claim review.

---

Key competitive landscape: who is most exposed to JAYPIRCA-driven share changes?

The most direct share risk is concentrated in competing BTK inhibitors and adjacent chemo-free strategies.

BTK competitor risk focus

• Covalent BTK competitors with strong presence in CLL/SLL and MCL are exposed to switching and sequencing shifts.
• Agents with higher discontinuation rates or less favorable tolerability profiles can lose incremental share, particularly in older patient cohorts.

Non-BTK oncology strategy risk

• Venetoclax-based regimens can face pacing pressure where physicians prefer tolerable continuous BTK therapy.
• Other targeted regimens (including BCL2, PI3K, and other novel mechanisms) can influence selection by line of therapy and molecular risk.

No quantifiable market share impact can be produced without market sizing inputs.

---

Financial trajectory: what metrics determine whether JAYPIRCA is compounding or plateauing?

A practical investment and licensing view centers on four metrics:

1. New patient starts (TRx trend and treatment initiations)
2. Persistence and discontinuation
3. Net price versus list price (rebates and discounts)
4. Mix shift by line of therapy and region

What financial pattern typically signals plateau risk

• Growth driven primarily by small incremental label expansions rather than sustained new patient starts
• Rising discontinuation reducing patient-level revenue retention
• Intensifying payer restrictions limiting access expansion
• Competitive switching back to lower-cost regimens

What signals renewed acceleration

• Broader label scope enabling use earlier in therapy sequencing
• New data expanding response depth or duration in additional subgroups
• Improved formulary access reducing step edits

No revenue numbers, guidance, or consensus forecast figures can be cited without source materials.

---

Key Takeaways

• JAYPIRCA’s market dynamics are driven by BTK switching behavior, tolerability-influenced persistence, and payer access constraints typical of continuous oral oncology therapy.
• Competitive pressure comes from covalent BTK inhibitors and venetoclax-based fixed-duration strategies, with sequencing decisions determining share.
• Exclusivity, patent term, and any Paragraph IV litigation determine generic entry timing and must be mapped from verified FDA listings to quantify erosion risk.
• A quantified financial trajectory requires validated revenue history and FDA/patent dossier facts that are not present in the prompt context.

---

FAQs

1. What patient populations are most likely to switch to JAYPIRCA after covalent BTK inhibitor intolerance or resistance?
2. How do payer prior authorization policies typically affect JAYPIRCA uptake in US commercial and Medicare plans?
3. Which endpoints and subgroup data most influence JAYPIRCA sequencing against venetoclax-based regimens?
4. What Orange Book patents most likely block generic ANDA entry for pirtobrutinib dosage forms?
5. What litigation milestones would materially affect the timing of potential generic launches for JAYPIRCA?

---

References

No sources were cited because no FDA/Orange Book, litigation, or company financial disclosure data was provided in the prompt context.

DrugChatter Q&A for JAYPIRCA

How long does it take for jaypirca to work?
Jaypirca pirtobrutinib annual cost price 2023?
Jaypirca availability at local pharmacies?
Jaypirca availability at pharmacies?
How does Jaypirca treat BTK-inhibitor resistant lymphoma?